Treprostinil

證據等級: L5

預測適應症: 10 個

Treprostinil: From Pulmonary Arterial Hypertension to Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

One-Sentence Summary

Treprostinil is a prostacyclin (PGI2/IP-receptor) analogue whose established therapeutic class is pulmonary arterial hypertension (WHO Group 1); it currently has no Danish marketing authorisation. The TxGNN model predicts it may be effective for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (CTD-PAH), with 1 clinical trial and a pool of 19 publications — including a tier-1 RCT and a 2024 systematic review/meta-analysis — supporting this direction.

Quick Overview

Item	Content
Original Indication	Not documented in Danish regulatory data (drug not currently marketed in Denmark); mechanistic rationale in the evidence pack identifies treprostinil as an established WHO Group 1 PAH therapy
Predicted New Indication	Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
TxGNN Prediction Score	99.55%
Evidence Level	L2
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

The evidence pack does not contain a validated original_moa record for treprostinil (flagged as a High-severity data gap, DG002), so the mechanistic picture below is drawn from the repurposing-rationale evidence rather than a verified DrugBank/SmPC entry and should be confirmed before final sign-off. According to that evidence, treprostinil is a prostacyclin (PGI2) analogue acting on IP receptors to produce pulmonary and systemic vasodilation, inhibit platelet aggregation, and suppress vascular smooth-muscle proliferation — the core pharmacological mechanism underlying WHO Group 1 pulmonary arterial hypertension therapy.

CTD-PAH is not a structurally distinct disease from the indications treprostinil already addresses — it is a well-recognized WHO Group 1 subgroup (most commonly arising in systemic sclerosis, followed by SLE and mixed connective tissue disease). This makes the prediction less a “repurposing into a new disease” and more a confirmation of applicability to an already-covered disease subtype. This is supported by a treprostinil-specific RCT subgroup analysis in CTD-PAH (Oudiz et al., 2004) and reinforced by a 2024 systematic review/meta-analysis of CTD-PAH treatment outcomes.

By contrast, the single highest raw TxGNN score in this evidence pack (99.7%, rank 1) points to “pulmonary arteriovenous malformation” — a structural vascular anomaly (typically HHT-related) rather than a vasoconstrictive/elevated-PVR disease. The evidence pack’s own reviewer notes flag this as a likely knowledge-graph proximity artifact (similar node naming to other PAH entities) rather than a genuine mechanistic signal: it carries zero supporting trials or literature and is scored L5/Hold. It is therefore not used as the featured indication in this report, even though its raw score is nominally higher than CTD-PAH’s.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02663895	Phase 2	Completed	12	Open-label pilot of oral treprostinil for 12 months in systemic sclerosis patients with calcinosis; primary endpoint was calcinosis reduction, not PAH — indirect supporting evidence only

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38378970	2024	Systematic Review / Meta-analysis	Internal and Emergency Medicine	Meta-analysis of RCT subgroup/post-hoc data on CTD-PAH treatment outcomes (functional class, survival, 6MWD, NT-proBNP)
11897647	2002	RCT	Am J Respir Crit Care Med	Pivotal double-blind, placebo-controlled trial of continuous subcutaneous treprostinil in PAH (Simonneau et al.), foundational efficacy/safety data for the drug class
15302727	2004	RCT subgroup analysis	Chest	Efficacy and safety of subcutaneous treprostinil specifically in CTD-associated PAH patients
40566626	2025	RCT (selexipag, same class, not treprostinil)	Life (Basel)	Selexipag in CTD-PAH with concomitant interstitial lung disease; supportive class-effect evidence
34462153	2021	Cohort	La Revue de Médecine Interne	Multicenter retrospective study characterizing CTD-PAH patients treated with prostanoids
35412560	2022	Review	JAMA	General PAH diagnosis and treatment review, contextualizing prostacyclin pathway therapies
41594679	2026	Review	Biomolecules	Current therapeutic strategies and future prospects for CTD-PAH
37765060	2023	Review	Pharmaceuticals (Basel)	Recent advances in treatment of CTD-associated PAH
16218473	2005	Review	Lupus	Overview of PAH associated with connective tissue diseases
22621693	2012	Review	Drugs	Treatment approaches for PAH in connective tissue disease

Denmark Market Information

Treprostinil currently holds no marketing authorisation in Denmark (0 authorisations on record; market status: Not marketed). No national (Lægemiddelstyrelsen) or centralised (EMA) licence data is available in this evidence pack.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Key warnings, contraindications, and drug-drug interaction data are not currently available in this evidence pack (DDI query status: not found).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: CTD-PAH is a well-established WHO Group 1 PAH subgroup with a directly relevant RCT subgroup analysis, a 2024 systematic review/meta-analysis, and a shared, already-validated prostacyclin mechanism — evidence level L2. However, treprostinil has zero current Danish marketing authorisations, and drug-level safety data are blocked by a data gap (DG001), so this cannot yet advance without additional safety documentation.

To proceed, the following is needed:

Danish/EU SmPC warnings and contraindications (currently blocking data gap DG001)
Verified DrugBank/product mechanism-of-action documentation (DG002)
Confirmation of Danish/EU marketing-authorisation or named-patient import pathway, given 0 current licences
Drug-drug interaction screening (currently “not found”)
Route-of-administration compatibility assessment (marked “pending” across all predicted indications in this pack)
Note: Two other PAH subtypes in this evidence pack — CHD-associated PAH (L2, Proceed with Guardrails) and HIV-associated PAH (L3, Research Question) — warrant separate evaluation; the highest raw-scoring prediction (pulmonary arteriovenous malformation, L5) is assessed by the evidence pack itself as a likely model artifact with no supporting trials or literature and should remain on Hold.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.